Identification and characterization of serovar-independent immunogens in Actinobacillus pleuropneumoniae
Antenucci, Fabio; Fougeroux, Cyrielle Elyette; Bosse, Janine T.; pdx366, pdx366; Roesch, Camille; Langford, Paul; Holst, Peter Johannes; Bojesen, Anders Miki

Published in: Veterinary Research

DOI: 10.1186/s13567-017-0479-5

Publication date: 2017

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Antenucci, F., Fougeroux, C., Bosse, J. T., Magnowska, Z., Roesch, C., Langford, P., ... Bojesen, A. M. (2017). Identification and characterization of serovar-independent immunogens in Actinobacillus pleuropneumoniae. DOI: 10.1186/s13567-017-0479-5
Identification and characterization of serovar-independent immunogens in *Actinobacillus pleuropneumoniae*

Fabio Antenucci, Cyrielle Fougeroux, Janine T. Bossé, Zofia Magnowska, Camille Roesch, Paul Langford, Peter Johannes Holst and Anders Miki Bojesen

**Abstract**

Despite numerous actions to prevent disease, *Actinobacillus pleuropneumoniae* (*A. pleuropneumoniae*) remains a major cause of porcine pleuropneumonia, resulting in economic losses to the swine industry worldwide. In this paper, we describe the utilization of a reverse vaccinology approach for the selection and in vitro testing of serovar-independent *A. pleuropneumoniae* immunogens. Potential immunogens were identified in the complete genomes of three *A. pleuropneumoniae* strains belonging to different serovars using the following parameters: predicted outer-membrane subcellular localization; ≤ 1 trans-membrane helices; presence of a signal peptide in the protein sequence; presence in all known *A. pleuropneumoniae* genomes; homology with other well-characterized factors with relevant data regarding immunogenicity/protective potential. Using this approach, we selected the proteins ApfA and VacJ to be expressed and further characterized, both in silico and in vitro. Additionally, we analysed outer membrane vesicles (OMVs) of *A. pleuropneumoniae* MIDG2331 as potential immunogens, and compared deletions in *degS* and *nlpI* for increasing yields of OMVs compared to the parental strain. Our results indicated that ApfA and VacJ are highly conserved proteins, naturally expressed during infection by all *A. pleuropneumoniae* serovars tested. Furthermore, OMVs, ApfA and VacJ were shown to possess a high immunogenic potential in vitro. These findings favour the immunogen selection protocol used, and suggest that OMVs, along with ApfA and VacJ, could represent effective immunogens for the prevention of *A. pleuropneumoniae* infections in a serovar-independent manner. This hypothesis is nonetheless predictive in nature, and in vivo testing in a relevant animal model will be necessary to verify its validity.

**Introduction**

*Actinobacillus pleuropneumoniae* (*A. pleuropneumoniae*) is a Gram-negative bacterium causing respiratory disease in pigs worldwide. *A. pleuropneumoniae* outbreaks are a constant threat to the pig farming industry, and are estimated to reduce the expected revenues in pig production by an average of 6.4€ per pig in affected herds [1]. To date, *A. pleuropneumoniae* has been divided into 16 serovars and 2 biovars, according to capsular antigens and nicotinamide dinucleotide (NAD) requirements [2–4], respectively. The spatiotemporal prevalence of individual serovars has been shown to vary, both regionally and over time [5].

The first generation of vaccines developed against *A. pleuropneumoniae* was based on inactivated whole cells (bacterins). Although in some cases effective in preventing both colonization and morbidity, these vaccines offered protection against little more than the specific serovar used for immunization [6, 7]. A step forward was made with the characterization of the Apx toxins, a set of four pore-forming cytolysins (Apx I-IV) centrally involved in *A. pleuropneumoniae* pathogenesis, and secreted by all *A. pleuropneumoniae* serovars in various combinations [3, 8]. Vaccines based on Apx toxins elicit a strong humoral response and are able to effectively reduce morbidity in vaccinated animals [9–12], but fail in preventing colonization and thus create the risk of the
spreading of disease by asymptomatic carriers [6, 11, 13]. Nonetheless, vaccines based on Apx toxins in combination with various outer membrane (OM) proteins (see [6] for a complete review of *A. pleuropneumoniae* OM immunogens) are the most widely used for the prevention of *A. pleuropneumoniae* infection. Thus, despite the availability of vaccines for *A. pleuropneumoniae*, their efficacy is challenged by limited prevention of host colonization [10, 14] or cross-serovar protection [11, 13, 15]. Hence a major challenge impeding development of an effective vaccine has been to identify immunogens capable of preventing colonization of the host by all known *A. pleuropneumoniae* serovars as well as the severity of the disease.

The selection of immunogens for vaccine development has for decades been a rather laborious process, usually requiring the isolation and testing of hundreds of potential immunogens from cultures with subsequent identification of the genes involved in their expression, and finally production of the chosen immunogens for in vitro and in vivo testing [16]. The advent of bioinformatics and the sequencing of bacterial genomes have allowed researchers to invert this workflow and identify instead potential immunogens at a genetic level. Once identified, candidate immunogens can be easily expressed using suitable vectors for subsequent testing. This alternative workflow has quite fittingly been called reverse vaccinology (RV) [17, 18], and has offered immunologists the opportunity to significantly reduce the workload traditionally necessary for vaccine development [19].

Similar to RV, bacterial outer membrane vesicles (OMVs) represent a revolution in the way non-live vaccines are now conceived and developed. The OMVs are vesicles secreted by the majority of Gram-negative bacteria that serve numerous biological functions, from cargo delivery to immune modulation [20, 21]. The OMVs are secreted during all phases of bacterial growth, and vary in size between 20 and 300 nm for Gram-negative bacteria [22, 23]. Secretion of OMVs has been proven to be negatively regulated by various genes, inactivation of which often leads to an enhanced secretion of OMVs [24]. Being released from the bacterial OM, OMVs generally represent antigenic properties very similar to intact bacteria. In addition, OMVs have a significant adjuvant potential due to the presence of lipopolysaccharides (LPS) and immunomodulatory proteins on their surface [25, 26]. The relatively high molecular mass of OMVs also allows for more cost-effective purification methods, as compared to recombinant antigens [27], leading to lower vaccine production costs [28, 29]. Additionally, the structure and biogenesis of OMVs offer the possibility to engineer them in order to add desired antigens, either to their surface or as cargo [30, 31]. However, immunization with OMVs also presents some risks. The presence of LPS on OMVs, for example, could pose a threat to the vaccinated individual, potentially causing Systemic Inflammatory Response Syndrome (SIRS) after immunization [32].

Both OMVs and proteins identified using RV are considered promising vaccines commodities, and have so far been utilized commercially in the widely used vaccine against *Neisseria meningitidis* [33]. Here we employ a similar methodology for the identification of serovar-independent immunogens as a first step in the development of a broadly protective vaccine against *A. pleuropneumoniae*.

### Materials and methods

**Bacterial strains, genomes, and sequence analysis**

The *A. pleuropneumoniae* strains and accession numbers for genomes used in this investigation are listed in Table 1. Unless otherwise stated, all sequence analysis programmes were used with default parameters. The pan-proteomes extracted from genomes of *A. pleuropneumoniae* JL03, L20 and AP76 strains (serovars 3, 5b, and 7, respectively) were analysed by PSORTb v3.0 [34]. Proteins whose subcellular localization was predicted as ‘OuterMembrane’ with a score > 9.00/10.00 were included in a preliminary candidate immunogen list (Additional file 1). The conservation of candidate immunogen genes across all published *A. pleuropneumoniae* genomes and strains included in this study

| Strain | Serovar | Genome assembly | Accession Number (NCBI) | Function |
|--------|---------|----------------|-------------------------|----------|
| *A. pleuropneumoniae* JL03 | 3 | CP0000687.1 | In silico identification of potential immunogens |
| *A. pleuropneumoniae* L20 | 5b | CP0000569.1 | |
| *A. pleuropneumoniae* AP76 | 7 | CP0001091.1 | |
| *A. pleuropneumoniae* MIDG2331 | 8 | NZ_LN908249.1 | OMV isolation and characterization |
| *A. pleuropneumoniae* MIDG2331 ΔnlpI | 8 | NA | |
| *A. pleuropneumoniae* HK361 | 2 | NA | In vitro immunogenicity assessment |

NCBI accession numbers are provided.

NA: non available.
genomes (those available in Genbank as of 14/02/17) was verified using BLASTn. Minimum and maximum conservation rates were noted in the preliminary candidate immunogen list (Additional file 1), as was the predicted presence or lack of a signal peptide, as detected by SignalP 4.1 [35], and the number of transmembrane helices (TMHs), as predicted by the TMHMM Server v. 2.0 [36]. Candidates with > 1 predicted TMH were discarded from further analysis. Preliminary candidate immunogens were screened for available data regarding their biological function and/or immunogenicity, narrowing down the initial list to 9 candidate immunogens (Table 2). Finally, ApfA and VacJ were chosen for expression and characterisation. The ApfA and VacJ three-dimensional protein structures were predicted using the I-TASSER server [37]. Highest confidence models were chosen as predicted structures (ApfA model C-score: −0.40; VacJ model C-score: −3.74).

Construction of ΔdegS & ΔnlpI mutants
The A. pleuropneumoniae serotype 8 MIDG2331 strain was engineered for the construction of individual ΔnlpI and ΔdegS mutants. The nlpI or degS genes of the wild type (wt) strain were each replaced with a synthesised (Eurofins Genomics) trfamethoprim resistance cassette consisting of the dfrA14 gene from plasmid pM3389T [38] under control of the A. pleuropneumoniae sodC promoter [39], and followed by the 9 bp sequence required for efficient uptake of DNA during natural transformation of A. pleuropneumoniae [40]. Gene replacement constructs were designed by In-Fusion cloning, with the dfrA14 cassette flanked by approx. 500 bases of sequence upstream and downstream of the gene to be replaced, as previously described [41]. Sequences were amplified using AccuPrime Taq DNA high-fidelity Polymerase (ThermoFisher Scientific). Briefly, primers (degS_left_for + degS_right_rev; nlpI_left_for + nlpI_right_rev; Table 3) were designed to amplify the left and right sequences flanking the gene to be deleted, with 15 bp extensions to allow directional cloning into the linear vector pJET1.2/blunt (ThermoFisher Scientific). The resulting plasmids, pJET-degS and pJET-nlpI were opened by inverse polymerase chain reaction (PCR), using degS_left_rev + degS_right_for and nlpI_left_rev + nlpI_right_for primer pairs (Table 3). The dfrA14 cassette was amplified and cloned into the inverse-amplified pJET-degS and pJET-nlpI plasmids, using primers with 15 bp extensions matching the ends of the linearized constructs (dfrA14 degS_for + dfrA14 degS_rev; dfrA14 nlpI_for + dfrA14 nlpI_rev; Table 3). The resulting plasmids, pJETΔdegS::dfrA14 and pJETΔnlpI::dfrA14 were linearized by digestion with FastDigest XbaI restriction enzyme (ThermoFisher Scientific) prior to natural transformation into A. pleuropneumoniae serotype 8 strain MIDG2331 [42], as previously described [41]. Transformants were selected on BHI (brain–heart infusion)-NAD containing 10 μg/mL trimethoprim, and the gene replacements were confirmed by PCR using primers designed to verify the location of the dfrA14 cassette insertion (degS_test + dfrA14_test_for; nlpI_test + dfrA14_test_rev; see Table 3).

OMV isolation and analysis
For isolation of OMVs from A. pleuropneumoniae MIDG2331 wt, ΔdegS and ΔnlpI clones, 600 mL of BHI-NAD broth was inoculated for each with a 1/10 volume of overnight (ON) culture (to an initial OD600 = 0.1 (OD: optical density) and incubated at 37 °C/200 rpm for

| Protein  | Accession Number (NCBI) | Function/putative role in virulence                                                                 |
|----------|-------------------------|-----------------------------------------------------------------------------------------------------|
| ApfA     | YP_001053581.1          | Fimbrial subunit protein, demonstrated role in A. pleuropneumoniae colonization and virulence [56] |
| APP7_2042| WP_005616333.1          | Putative ligand-gated iron transporter                                                               |
| HecB     | ACE61667.1              | Hemolysin activation protein and putative virulence factor in Arcobacter butzleri [67]             |
| HgbA     | YP_001053746.1          | Hemoglobin binding protein, A. pleuropneumoniae ΔhgbA mutants exhibit an attenuated virulence [54] |
| Irp      | ABN74015.1              | Iron-regulated OM receptor/transporter possibly involved in hemin transport, upregulated in A. pleuropneumoniae after colonisation [58] |
| OstA     | YP_001053661.1          | Organic solvent tolerance protein in Helicobacter pilori. OstA inactivation causes altered membrane permeability, sensitivity to organic solvent and susceptibility to antibiotics [68] |
| PepN     | ABN74424.1              | Multi-subunit transmembrane metalloprotease able to degrade porcine IgA and IgG, expressed during A. pleuropneumoniae infection in vivo [55] |
| SlyB     | ABN73145.1              | Outer membrane lipoprotein, contributes to cell envelope integrity in Burkholderia multivorans [69] and is linked to the stress response to Mg2+ depletion [70] |
| VacJ     | YP_001054603.1          | OM lipoprotein, Pasteurella multocida VacJ protein moderately immunogenic and protective when inoculated in vivo [63] |

NCBI accession numbers are provided.
Expression and purification of recombinant ApfA and VacJ

The apfA and vacJ genes were amplified from genomic DNA using Phusion Hot Start II DNA high-fidelity Polymerase (ThermoFisher Scientific) and cloned into the pET-44 Ek/LIC Vector (Merck Millipore) by In-Fusion directional cloning (Clontech). Briefly, primers were designed to open the vector by inverse PCR (pET44_apfA_rev + pET44_apfA_for), and to amplify the genes (apfA_pET44_for + apfA_pET44_rev; vacJ_pET44_for + vacJ_pET44_rev; see Table 3). The gene specific primers did not include the start or stop codons, as these were supplied by the vector. For all primers, 15 bp extensions were added to the 5’ ends, providing reciprocal regions of complementarity (30 bp total) for In-Fusion cloning. The In-Fusion reactions were initially performed with the correct inserts were designated pApfA exprn and pVacJ exprn (n = 1–3).

For large-scale purification of expressed ApfA and VacJ proteins, the appropriate clones were inoculated into 800 mL of pre-warmed 2YT-Amp broth, using a 1/10 dilution of an ON starter culture, and incubated at 37 °C, 150 rpm, until OD600 reached 0.5–0.8. At this point, the incubation temperature was shifted to 20 °C, and 20 min later protein expression was induced by addition of 400 µL of 1 M IPTG to a final volume of 300 mL prior to being re-concentrated in a second round of HF. The following day, the concentrate was filtered through a 0.45 µm filter and statically dialysed 1:1000 in sterile PBS (3 h, 4 °C). The dialysed samples were then further concentrated using Amicon Ultra-15 Centrifugal Filter Units (Merck Millipore) to a final volume of 3 mL (i.e. 200-fold concentration).

Samples were analysed by transmission electron microscopy (TEM). Carbon-coated laminae were suspended into the OMV solutions for a few seconds and soaked with a droplet of 2% (w/v) phosphotungstic acid. Grids were soaked into a Sellotape/Chlorophorm solution to increase adherence and then placed on the laminae. After 1–2 min, the Grids were removed and left to dry on filter paper. Once dried, stained grids were examined using a Philips CM100 Transmission Electron Microscope (Philips). Additionally, aliquots of the OMV samples were quantified by tunable resistive pulse sensing (TRPS) using a qNano device (Izon Sciences Ltd) following the protocol recommended by the operator [44]. Data were analyzed using the proprietary data capture and analysis software, Izon Control Suite V.3.3.2.2001.

Table 3 Primers used in this study

| Primer         | Sequence (5’–> 3’) |
|---------------|-------------------|
| deg5_left_for | GAAATTCCTGACGCGGAGAAGGTGCTAATATATGATG |
| deg5_left_rev | CCAAGGTGTTAAGAACCCTAGTGGCAATGTTG |
| deg5_right_for | TTGACGGAGGCGTTACAAGTGGCAGAAGGTCGTAAACG |
| deg5_right_rev | ACTTAGTGATGCCCCCGGAACCTCAACGTTTACCTC |
| nplI_left_for | CGTATGGTGGTTGTTGTTG |
| nplI_right_for | TGCCGTTAGCTGTGCTGTTG |
| dfrA14-test-for | TCGTTTCAACCTTGGTGTTTGG |
| dfrA14-test-rev | GTCCCAAGGAAGAAGCAGAGAAGTCAATGCTTACG |
| apfA_pET44_for | ACTTTAGTACTATTAGTCTATACCT |
| apfA_pET44_rev | TTGACGGAGGGCGTTACCTTGGG |
| vacJ_pET44_for | ACTAGTGGATCCCCCGCAACCTCACGATTTCTATCTC |
| vacJ_pET44_rev | TTGACGGAGGGCGTTACCTTGGG |
| Lower case letters indicate nucleotides modified from the target sequence in order to reduce primer secondary structure formation. |
(isopropil-β-D-1-tiogalattopiranoside). Cultures were then left to incubate ON at 20 °C, 150 rpm. Cell pellets were harvested by centrifugation (10 000 g, 10 min, 4 °C) and then kept on ice. Pellets were resuspended in lysis buffer (2 mL/g of pellet) and sonicated twice (80% Power, 5 pulsations, 5 min, 4 °C, 25 W effective). Cell lysates were centrifuged (40 000 g, 30 min, 4 °C), and supernatants were filtered on ice through 0.2 μm filters. A list of the non-commercial buffers used is provided in Additional file 2.

The recombinant proteins were isolated from the supernatants by immobilized ion metal affinity chromatography (IMAC) using the ÄKTAxpress chromatography system (GE Healthcare). Supernatants were loaded and run on HisTrap SP-HP 5 mL columns (GE Healthcare) following the manufacturer’s recommendations. The extinction coefficients of the recombinant proteins were calculated using the ExPASy ProtParam tool [45] and uploaded to the ÄKTAxpress managing program, in order to identify (by OD_{280} absorbance) the fractions containing proteins after purification. Selected protein fractions were pooled on ice, transferred to a 6–8 kD dialysis membrane (Spectra/por), and dialysed ON in 4 l PBS. Protein profiles of the purified fractions were compared to that of the initial filtered supernatant by electrophoresis under denaturing conditions using NuPAGE™ (polyAcrylamide gel electrophoresis) 4–12% Bis–Tris Protein sodium dodecyl sulphate (SDS) Gel (ThermoFisher Scientific), run for 1 h at 180 V, and stained with Coomassie Blue. Tags were removed from the purified proteins by cleavage with human plasma thrombin (Merck Millipore)(~2 U thrombin/μg of protein, 37 °C, ON), and separation by size exclusion chromatography (SEC). Proteins were loaded and run on Superdex 75 PG columns (GE Healthcare) using the ÄKTAxpress chromatography system. Fractions containing ApfA and VacJ proteins were identified, collected and dialyzed as described above.

Analysis of serum samples by ELISA
Control pig serum samples were obtained from Danish pig herds participating in the specific pathogen free (SPF) system. All herd are tested for A. pleuropneumoniae serovars 1, 2, 5, 6, 7, 10 and 12, respectively, using ELISA (enzyme-linked immunosorbent assay) methods previously described [46]. Convalescent sera from pigs experimentally infected with A. pleuropneumoniae serotype 2 HK361 were also used. All animals were otherwise classified as pathogen-free. Details regarding all sera used in this study are provided in Table 4.

Antibody (IgG) responses to purified ApfA and VacJ were determined by ELISA. Briefly, 96-well flat bottom plates (TPP) were coated with 100 ng of protein/well in PBS, and incubated at 4 °C ON. Pig sera (negative controls and samples known to be positive for serovars 2, 6 and 12, respectively) were diluted threefold between 1:500 and 1:1 093 500 in diluent buffer, and incubated for 1 h at room temperature (RT). Bound antibodies were detected with peroxidase labelled rabbit anti-pig IgG (ThermoFisher Scientific) at a 1:15 000 dilution, followed by colorimetric detection (OD_{450}) with TMB2 PLUS2 substrate (Kem-En-Tec Diagnostics), according to the manufacturer’s protocol. A list of the non-commercial buffers used is provided in Additional file 2. The four data sets (Control, A. pleuropneumoniae serotype 12, 2, 6) from ApfA and VacJ ELISA assays were transformed to Log10 values and analysed by D’Agostino and Pearson omnibus normality test to verify the assumption of Gaussian distribution of the data sets (alpha = 0.05). Data sets were subsequently converted to area under curve (AUC) values and analysed by Ordinary one-way ANOVA (P < 0.05) to verify their statistical significance. When overall statistical significance was achieved by ANOVA, data were analysed by post hoc Holm-Sidak test to assess statistical differences between individual groups and controls. P < 0.05 were again considered statistically significant. All statistical analyses were performed using GraphPad Prism 6.0c (GraphPad Software, La Jolla California USA). A summary of the statistical results obtained is provided in Additional file 3.

| Serum | Serovar specificity | Mode of infection |
|-------|---------------------|------------------|
| App 2 | A. pleuropneumoniae serovar 2 | Natural |
| App 6 | A. pleuropneumoniae serovar 6 | Natural |
| App 12 | A. pleuropneumoniae serovar 12 | Natural |
| Naive | // | Uninfected |
| App HK361 | A. pleuropneumoniae HK361 : serovar 2 | Experimental |

2D SDS-PAGE and Western blot
Proteins from OMV isolates of A. pleuropneumoniae 2331 wt and ΔnlpI mutant, containing equal number of vesicles, were purified by Wessel-Flüge extraction [47]. Prior to IsoElectric Focusing (IEF), immobilized pH gradient (IPG) strips (pH 4-7, 7 cm, GE Life Sciences) were rehydrated in DeStreak rehydration solution (GE Life Sciences)(1.5% IPG buffer, pH 4-7, ON). The samples were applied using the cup-loading method and IEF was performed at a total of 7 kVh per strip on an Ettan IEFphor isoelectric focusing unit (GE Life Sciences). IPG strips were subsequently reduced, alkylated and proteins were separated in duplicates by 2D SDS-PAGE as a second dimension using NuPAGE 4–12% Bis–Tris ZOOM gels (Invitrogen) in running conditions as described above.
for standard SDS-PAGE. The other set of gels was transferred to polyvinylidene difluoride (PVDF) membranes using an iBlot® Gel Transfer Device (Thermofisher Scientific) for Western blotting. Pig sera from controls and animals that were challenged with live *A. pleuropneumoniae* HK361 cells were used as 1st Ab, 1:2000 dilution. A commercial Anti-Swine *IgG (H + L)-Alkaline Phosphatase* antibody (Sigma Aldrich) was used as 2nd Ab, 1:10 000 dilution. Bands were revealed by 30 min incubation with dissolved SIGMAFAST™ BCIP®/NBT (5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium) tablets (Sigma Aldrich). A list of the non-commercial buffers used is provided in Additional file 2.

**Results**

**In silico selection of conserved immunogens**

A list of all potential immunogens initially identified is shown in Additional file 1. Only proteins predicted to be localised in the OM, and having \( \leq 1 \) TMH, were included; likely secreted candidates were discarded. Details regarding predicted function and immunogenicity (based on published data) were used to narrow down the list of potential immunogens to 9 candidates (Table 2). From the 9 candidates, ApfA and VacJ proteins were selected for expression and in vitro characterization.

**Preparation of recombinant proteins and OMVs**

Both *apfA* and *vacJ* were successfully cloned into the pET-44 Ek/LIC vector, resulting in plasmids pET-44-*apfA* and pET-44-*vacJ*. Expression of protein from *E. coli* strains harbouring these plasmids yielded a total of 46 mg and 18 mg protein for ApfA and VacJ, respectively, prior to tag removal. Following tag removal, two protein-containing fractions were isolated (Figure 1), however purified proteins were derived only from the fractions showing higher concentration and purity (i.e. the second fraction for each of ApfA and VacJ). The final protein yields were 7.4 mg for ApfA, and 4.25 mg for VacJ.

![Figure 1 1D SDS-PAGE analysis of purified ApfA and VacJ proteins.](image)

Tags were removed from the expressed recombinant proteins by thrombin cleavage. Subsequently, proteins + tags were loaded on an AKTAxpress chromatography system and purified by size exclusion chromatography (SEC). A ApfA SEC; B VacJ SEC; Input: Proteins + cleaved tags before SEC; Fractions 1–2: Isolated fractions of purified ApfA and VacJ proteins after SEC. ApfA and VacJ proteins are indicated by black arrows. The size of selected bands of the protein marker in kilodaltons (kDa) is shown. ApfA theoretical molecular weight: 20 kDa; VacJ theoretical molecular weight: 27 kDa; Human thrombin molecular weight: 37 kDa.
The OMVs isolated by HF from wt, ΔdegS and ΔnlpI mutants were analysed by TEM (Figure 2) and precisely quantified and measured by TRPS analysis (Figure 3). Both ΔdegS and ΔnlpI mutants showed increased OMV secretion as compared to the wt. The size distribution of the OMVs was also affected, with a wider variation in diameter range recorded for both mutants (Figure 3).

Figure 2 Transmission electron microscopy (TEM) analysis of A. pleuropneumoniae outer membrane vesicles (OMVs). TEM images show OMVs isolated from A. pleuropneumoniae MIDG2331 wild-type (A) and ΔdegS (B), ΔnlpI (C) mutants. Red arrows indicate OMVs.

Figure 3 TRPS analysis of OMVs. TRPS analysis of OMVs from A. pleuropneumoniae MIDG2331 wt (A), ΔdegS (B) and ΔnlpI (C) mutants. Size distribution and concentration of OMV samples are shown on individual graphics and resumed on the table on the right side of the figure.
Assessment of in vitro immunogenicity

Convalescent sera from animals naturally infected with *A. pleuropneumoniae* serovars 2, 6 or 12, respectively, showed a significantly higher median IgG response against both ApfA and VacJ than the control sera from uninfected pigs (Figure 4). Statistical analysis of the data sets showed the significance of the differences observed between groups in IgG levels for both ApfA and VacJ \( (P < 0.05; \) Additional file 3). Similarly, the Western blot (WB) analysis with sera from animals experimentally infected with *A. pleuropneumoniae* HK361 (serovar 2) showed a strong IgG response to both wt and ΔnlpI OMVs, and the presence of several particularly immunogenic proteins (Figure 5, only ΔnlpI OMVs shown).

**Discussion**

The development of new vaccines is predicted to become increasingly important in the fight against bacterial pathogens, due to the emergence of multidrug-resistant strains, and the dwindling number of new antimicrobials...
released on the market during the recent decades [48]. Accordingly, several new strategies for the identification of potential immunogens have been proposed and implemented [16]. Most of these strategies make use of the wide range of genome sequences and bioinformatic tools, and are sometimes collectively characterized as “immunoinformatics” [49]. Despite their obvious hypothetical nature, these computational predictions and in silico analyses have proven effective in the development of at least one commercial vaccine [33].

Subcellular localization is intuitively important when selecting potential immunogens. Intracellular or periplasmic antigens are not highly accessible to the host immune system, and usually do not play a significant role in the development of adaptive immunity against extracellular bacteria [50]. On the other hand, secreted proteins are usually highly immunogenic and quite often centrally involved in the bacterial pathogenesis (e.g. toxins), but being detached from the cell they fail in many instances in providing protection against bacterial colonization when administered as vaccines [13, 15, 51]. These and other previously described considerations led us to focus our analysis on OM proteins. Some of the identified candidates are A. pleuropneumoniae proteins involved in iron acquisition from the host (see Table 2), and limiting access to free iron has been proven to severely affect bacterial growth during infection [52, 53]. A. pleuropneumoniae represents no exception, and for instance the inactivation of the hgbA gene has been linked to reduced virulence in vivo [54]. PepN is another interesting candidate immunogen in our list, a protease able to degrade porcine IgA and IgG [55]. It is intuitive to understand how targeting antibody degradation could be beneficial in reducing A. pleuropneumoniae resistance to the host immune system. However, the most promising vaccine candidate antigens that we chose to investigate in this study were ApfA and VacJ.

Type IV fimbrial subunit protein ApfA is a well characterised virulence factor in A. pleuropneumoniae, whose potential as an immunogen has been preliminarily investigated in swine and mouse models of infection [11, 56, 57]. ApfA is an OM pilin involved in the early stages of host colonization, and its operon has been proven to be overexpressed during cell adhesion in vitro [58]. Cell adhesion represents one of the first steps involved in the colonization of host surfaces by a pathogenic bacterium [59], providing an ideal target for immunisation of the host with a view to blocking infection. To date, ApfA's potential as a protective immunogen remains controversial, with some data suggesting it may be able to confer partial protection [11, 56], while others suggest ApfA may interfere with the development of an adaptive response when included in a multicomponent vaccine formulation [57]. Our data confirmed ApfA conservation among all known A. pleuropneumoniae serovars. Furthermore, we demonstrated that ApfA is not only expressed by A. pleuropneumoniae in vitro or during a challenge in an induced animal model, but also during a natural infection in pigs, eliciting a rather marked humoral immune response in animals infected by at least 3 different A. pleuropneumoniae serovars not previously investigated. Finally, protein domain profiling of ApfA allowed us to identify a highly conserved helical domain, common to many pilins across species, that could be potentially used as an OM “anchor” for the construction of chimeras for antigen enrichment of the bacterial OM or OMVs.

VacJ (virulence-associated chromosome locus J) is an OM lipoprotein partially conserved among several Gram-negative pathogenic bacteria, including A. pleuropneumoniae. VacJ is part of a proposed phospholipid transporter (VacJ/Yrb ABC transporter), the inactivation or deletion of which has recently been shown to increase OMV secretion in some species [60]. In A. pleuropneumoniae, VacJ has been shown to be involved in OM integrity, serum resistance and biofilm formation [61]. As its name suggests, VacJ has been proposed as potential immunogen, and proven necessary for intracellular motility of Shigella flexneri [62]. Furthermore, the protective potential of a VacJ immunization has been described in at least one case, for Pasteurella multocida [63], whose VacJ protein shares 59% homology with the A. pleuropneumoniae homolog. As for ApfA, our data have shown that VacJ is highly conserved, expressed by A. pleuropneumoniae during a natural infection, and able to induce a specific immune response in pigs.

The potential use of OMVs as immunogens has been extensively investigated in several bacterial species, including other Pasteurellaceae [64]. Bacterial OMVs have been shown to contain most of the antigens embedded in the OM, including LPS, toxins and other surface antigens [20]. Most notably, A. pleuropneumoniae OMVs were previously shown to carry Apx toxins and proteases [65]. Our data provides further insight into the immunogenicity of A. pleuropneumoniae OMVs, with WB profiles indicating the presence of several highly immunogenic antigens, recognised by sera from animals infected with A. pleuropneumoniae serovars different than that used for isolation of the OMVs. The identity of these antigenic determinants is yet to be clarified, but it is likely that they include conserved proteins and virulence factors in addition to the Apx toxins and proteases previously described [63]. Furthermore, the choice of HF as purification technique allowed the concentration of large volumes of bacterial cell-free culture supernatants, increasing OMV yield when compared to gel filtration and gradient centrifugation methods, traditionally employed in OMV
isolation [27]. The ability to purify large batches of OMVs may prove very useful in the process of standardizing immunization protocols, where a large number of animals need to be vaccinated with the same sample.

In conclusion, our data support the potential of in silico identification of immunogens, and confirm the predicted high immunogenicity of A. pleuropneumoniae OMVs. Both ApfA and VacJ were shown to be expressed during infection by all the A. pleuropneumoniae serovars tested and thus may offer the long sought cross-serovar immunological potential. Accordingly, we hypothesize that OMVs, as well as ApfA and VacJ proteins, could be administered individually or as a combined vaccine for prevention of infection in pigs against all known A. pleuropneumoniae isolates. Nonetheless, in silico and in vitro analysis can only provide predictive information regarding the immunogenic potential of ApfA, VacJ and OMVs. In some instances in fact OM proteins have been described to produce a deleterious effect when employed as immunogens to vaccinate pigs [66], and accordingly in vivo testing in a relevant animal model (swine) will be required to verify the effective potential of ApfA, VacJ and OMVs as immunogens.

Additional files

Additional file 1. Preliminary list of A. pleuropneumoniae immunogen candidates. The table lists candidate immunogens identified after the initial in silico screening of the proteomes of A. pleuropneumoniae JU03, L20 and AP76 strains.

Additional file 2. List of non-commercial buffers used. The table lists the formulation of all the non-commercial buffers used during this study.

Additional file 3. Resume of the statistical tests performed in the study. The table lists statistical tests and parameters used to analyse the data produced during this study.

Abbreviations

A. pleuropneumoniae: Actinobacillus pleuropneumoniae; NAD: nicotinamide dinucleotide; OM: outer membrane vesicle; RV: reverse vaccinology; OMV: outer membrane vesicles; LPS: lipopolysaccharide; SIRS: systemic inflammatory response syndrome; TMH: trans-membrane helix; wt: wild type; BHI: brain–heart infusion; PCR: polymerase chain reaction; ON: overnight; OD: optical density; H: hydrostatic filtration; MWCO: molecular weight cut-off; PBS: phosphate buffered saline; TEM: transmission electron microscopy; TRPS: tunable resistive pulse sensing; E. coli: Escherichia coli; IPTG: isopropyl-β-D-1-thiogalactopyranoside; IMAC: ion metal affinity chromatography; PAGE: polyAcrylamide gel electrophoresis; SDS: sodium dodecyl sulphate; SPF: specific pathogen free; ELISA: enzyme-linked immunosorbent assay; RT: room temperature; AUC: area under curve; IEF: IsoElectric Focusing; IPG: immobilized pH gradient; PVD: polyvinylidene difluoride; 1Ab: primary antibody, 2Ab: secondary antibody; BCIP/NBT: 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium; WB: Western blot; VacJ: virulence-associated chromosome locus J; NCBI: national center for biotechnology information; CFU: colony forming unit; SEC: size exclusion chromatography.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

Design of study: AMB, PJH. In silico analysis: FA. Plasmid engineering and mutant construction: FA, JTB, PL. OMV isolation and imaging: FA. OMV quantification: CR. Protein expression and purification: FA, CF. CD SDS-PAGE: ZM. Immunological assays: FA, CF. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank Senior Veterinarian Dr. Solveig Harksen (SEGES Pig Research Centre, Copenhagen, Denmark) for providing some of the pig sera mentioned in this study. Special thanks go to Prof. Klaus Quortrup and Michael Johnson (Core Facility for Integrated Microscopy (CFIM), Faculty of Health and Medical Sciences, University of Copenhagen, Denmark), for their invaluable help during TEM imaging. Finally, we would like to thank Chris Janitzek for the assistance provided in protein isolation and purification.

Author details

1 Department of Veterinary and Animal Sciences, University of Copenhagen, Stigbølgen 4, 1870 Frb. C., 1-20, Building: 301, Copenhagen, Denmark. 2 Department of International Health, Immunology and Microbiology ISIM, University of Copenhagen, Øster Farimagsgade 5, Bldg 22/23, København K, 1014 Copenhagen, Denmark. 3 Department of Medicine, St Mary’s Campus, Imperial College London, 236 Wright Fleming Wing, London, UK. 1/14 Science Ltd, Bâtiment Laennec, 60 Avenue Rockefeller, 69008 Lyon, France.

Funding

The project was partly funded by The University of Copenhagen, Center for Control of Antimicrobial Resistance (UC-Care) and the Center for Research in Pig Production and Health (CPH Pig) at University of Copenhagen. Funding for research activities in UK was provided by the Biotechnology and Biological Sciences Research Council (BB/M023052/1).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 29 June 2017 Accepted: 20 October 2017

Published online: 09 November 2017

References

1. PROHEALTH Economic impact of Actinobacillus pleuropneumoniae. http://www.fp7-prohealth.eu/news-index/newsletter-november-2015/product-diseases-cost-pig-pigmucros/. Accessed 4 Apr 2017

2. Bossé JT, Li Y, Sárközi R, Gottschalk M, Angen Ø, Nedbalcova K, Rycroft AN, Fodor L, Langford PR (2017) A unique capsule locus in the newly designated Actinobacillus pleuropneumoniae serovar 16 and development of a diagnostic PCR assay. J Clin Microbiol 55:902–907

3. Bossé JT, Janson H, Sheehan BJ, Beddek AJ, Ryccroft AN, Simon Kroll J, Langford PR (2002) Actinobacillus pleuropneumoniae: pathobiology and pathogenesis of infection. Microbes Infect 4:225–235

4. Sárközi R, Makrai L, Fodor L (2015) Identification of a proposed new serovar of Actinobacillus pleuropneumoniae: Serovar 16. Acta Vet Hung 63:444–450

5. O’Neill C, Jones SCP, Bossé JT, Watson CM, Williamson SM, Rycroft AN, Kroll JS, Hartley HM, Langford PR (2010) Prevalence of Actinobacillus pleuropneumoniae serovars in England and Wales. Vet Rec 167:661–662

6. Rampeet M, Deslandes V, Gouré J, Jacques M (2008) Actinobacillus pleuropneumoniae vaccines: from bacterins to new insights into vaccination strategies. Anim Health Res Rev 9:25–45

7. Hersel A, Huter V, Katinger A, Raza P, Strnistschie C, Roesler U, Brand E, Lubitz W (2009) Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state. Vaccine 18:2945–2955

8. Negrete-Abascal E, Tenorio VR, Guerrero AL, García RM, Reyes ME, de la Garza M (1998) Purification and characterization of a protease from...
Actinobacillus pleuropneumoniae serotype 1, an antigen common to all the serotypes. Can J Vet Res 62:183–190
9. Reimer D, Frey J, Jansen R, Veit HP, Inzana TJ (1995) Molecular investiga-
tion of the role of Apol and Apoli in the virulence of Actinobacillus pleuropneu-
moniae serotype 5. Microb Pathog 18:197–209
10. Chiers K, van Overbeke I, De Laender P, Ducatelle R, Carel S, Haesebroeck F (1998) Effects of endobronchial challenge with Actinobacillus pleu-
ropneumoniae serotype 9 of pigs vaccinated with inactivated vaccines containing the Apx toxins. Vet Q 20:65–69
11. Sadilkova L, Nepereny J, Vizal V, Sebo P, Discka R (2012) Type IV fimbrial subunit protein AgFA contributes to protection against porcine pleuropneu-
monia. Vet Res 43:2
12. Del Pozo Sacristán R, Michels A, Martens M, Haesebroeck F, Maes D (2014) Efficacy of vaccination against Actinobacillus pleuropneumoniae in two Belgian farrow-to-finish pig herds with a history of chronic pleurisy. Vet Rec 174:302
13. Tumamao QJ, Bowles RE, van den Bosch H, Klaassen HLM, Fenwick BW, Storie GJ, Blackall PJ (2004) Comparison of the efficacy of a subunit and a live streptomycin-dependent porcine pleuropneumonia vaccine. Aust Vet J 82:370–374
14. Satran P, Nedbalcová K, Kuáerová Z (2003) Comparison of protection effi-
cacy of toxoid and whole-cell vaccines against porcine pleuropneumonia caused by endobronchial infection with Actinobacillus pleuropneumoniae. Acta Vet Brno 72:213–219
15. Van Overbeke I, Chiers K, Ducatelle R, Haesebroeck F (2001) Effect of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 9 of pigs vaccinated with a vaccine containing Apx toxins and transferrin-binding proteins. J Vet Med B Infect Dis Vet Public Health 48:15–20
16. Strugnell R, Zepp F, Cunningham A, Tantawichien T (2011) Vaccine anti-
gens. Perspect Vaccinol 1:61–88
17. Seib KL, Zhao X, Rappuoli R (2012) Developing vaccines in the era of 
genomics: a decade of reverse vaccination. Clin Microbiol Infect 18:109–116
18. Sette A (2010) Reverse vaccinology: developing vaccines in the era of 
genomics. Immunity 33:530–541
19. Rappuoli R (2008) Reverse vaccinology. Curr Opin Microbiol 3:445–450
20. Kulp A, Kuehn MJ (2010) Biological functions and biogenesis of secreted 
bacterial outer membrane vesicles. Annu Rev Microbiol 64:163–184
21. Kaparakis-Laskos M, Ferreiro RL (2015) Immune modulation by bacterial 
outer membrane vesicles. Nat Rev Immunol 15:375–387
22. Beveridge TJ, Makin SA, Kadurugamuwa JL, Litz (1997) Interactions 
between biofilms and the environment. FEMS Microbiol Rev 20:291–303
23. Olsen I, Amano A (2015) Outer membrane vesicles—offensive weapons or 
good samaritans? J Oral Microbiol 7:27468
24. McBroom AJ, Johnson AP, Vemulapalli S, Kuehn MJ (2006) Outer mem-
brane vesicle production by Escherichia coli is independent of membrane 
J Bacteriol 188:5385–5392
25. van der Pol L, Stork M, van der Ley P (2015) Outer membrane vesicles as 
platform vaccine technology. Biotechnol J 10:1689–1706
26. Sanders H, Feavers IM (2011) Adjuvant properties of meningococcal outer 
membrane vesicles and the use of adjuvants in Neisseria meningitidis 
protein vaccines. Expert Rev Vaccines 10:323–334
27. Klimentova J, Stulk J (2015) Methods of isolation and purification of 
outer membrane vesicles from gram-negative bacteria. Microbiol Res 170:1–9
28. Nieves W, Askarah S, Qazi O, Brown KA, Kurtz J, Auccin OP, Mclachlan JB, 
Roy CJ, Morici LA (2011) A naturally derived outer-membrane vesicle 
vaccine protects against lethal pulmonary Burkholderia pseudomallei 
chronicle. Pathog Glob Health 105:305–316
29. Yu NY, Wagner JR, Laird MR, Melli G, Rey S, Lo R, Diao P, Cenik Sahinalp S, 
Ester F, Foster LJ, Brinkman FSL (2010) PSORTB 3.0: improved protein 
subcellular localization prediction with refined localization subcat-
egories and predictive capabilities for all prokaryotes. Bioinformatics 
26:1608–1615
30. Petersen TN, Brunak S, von Heijne G, Nielsen H (2011) SignalP 4.0: 
discriminating signal peptides from transmembrane regions. Nat Methods 8:785–786
31. Krogh A, Larsson B, von Heijne G, Sonnhammer EL (2001) Predicting 
transmembrane protein topology with a hidden Markov model: applica-
tion to complete genomes. J Mol Biol 305:567–580
32. Roy A, Kucukural A, Zhang Y (2010) TASSER: a unified platform for auto-
mated protein structure and function prediction. Nat Protoc 5:725–738
33. Bossé JT, Li Y, Walker S, Atherton T, Fernandez Crespo R, Williamson SM, 
Rogers J, Chaudhuri RR, Weinert LA, Oshota O, Holden MTG, Maskell DJ, 
Tucker AW, Wren BW, Rycoft AN, Langford PR (2015) Identification of 
dfrA14 in two distinct plasmds conferring trimethoprim resistance in 
Actinobacillus pleuropneumoniae. J Antimicrob Chemother 70:2217–2222
34. Bossé JT, Durham AL, Rycoft AN, Kroll JS, Langford PR (2009) New 
plasmid tools for genetic analysis of Actinobacillus pleuropneumoniae and 
other pasteurellaceae. Appl Environ Microbiol 75:612–6131
35. Bossé JT, Nash JHE, Simon Kroll J, Langford PR (2004) Harnessing natural 
transformation in Actinobacillus pleuropneumoniae: a simple method for 
allicic replacements. FEMS Microbiol Lett 233:277–281
36. Bossé JT, Soares-Bazzoli DM, Li Y, Wren BW, Tucker AW, Maskell DJ, Rycoft AN, 
Langford PR (2014) The generation of successive unmarked muta-
tions and chromosomal insertion of heterologous genes in Actinobacillus 
pleuropneumoniae using natural transformation. PLoS One 9:111252
37. Bossé JT, Chaudhuri RR, Li Y, Leane LG, Fernandez Crespo R, Coupland P, 
Holden MTG, Bazzoli DM, Maskell DJ, Tucker AW, Wren BW, Rycoft AN, 
Langford PR (2016) Complete Genome sequence of MID2351, a geneti-
ically tractable serovar 8 clinical isolate of Actinobacillus pleuropneumona-
iae. Genome Announc 4:e00667
38. Musante L, Tataruch D, Gu D, Benito-Martín A, Calzafemti G, Aherne S, 
Holtzheimer H (2014) A simplified method to recover urinary vesicles for 
clinical applications, and sample banking. Sci Rep 4:7532
39. Blundell EL, Cogin R, Plat M (2016) Particle-by-particle charge analysis of 
DNA-modified nanoparticles using tunable resistive pulse sensing. 
Langmuir 32:1082–1090
40. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, 
Bairoch A (2005) Protein identification and analysis tools on the ExPasy 
server. In: Proteomics Protoc. Handb pp 571–607
41. Nielsen R, Planbeck T, Foged NT (1991) Blocking enzyme-linked immuno-
assay-based assay for detection of antibodies to Actinobacillus pleuropneu-
moniae serotype 2. J Clin Microbiol 29:794–797
42. Wessel D, Flugge UI (1984) A method for the quantitative recovery of protein 
in dilute solution in the presence of detergents and lipids. Anal Biochem 138:141–143
43. Bassetti M, Merelli M, Temporelli C, Astilean A (2013) New antibiotics for 
bad bugs: where are we? Annu Clin Microbiol Antimicrob 12:22
44. Tomar N, De RK (2014) Immunoinformatics: a brief review. Methods Mol 
Biol 1184:23–55
45. Ellis DW, Brodeur BR (2003) New bacterial vaccines. Springer, Berlin
46. Spencer J, Leuzzi R, Buckley A, Irvine J, Candlish D, Scarselli M, Douce 
Rogers J, Chaudhuri RR, Leane LG, Irvine J, Candlish D, Scarselli M, Douce 
G-Y, Kim Y-KY-S, Gho YS (2010) Outer membrane vesicles derived from 
Escherichia coli induce systemic inflammatory response syndrome. PLoS 
One 5:e11334
47. Vernikos G, Medini D (2014) Bexsero®. chronicle. Pathog Glob Health 
108:305–316
48. Antenucci et al. Vet Res (2017) 48:74
Page 11 of 12
metalloprotease: cloning and in vivo expression. FEMS Microbiol Lett 234:81–86
56. Zhou Y, Li L, Chen Z, Yuan H, Chen H, Zhou R (2013) Adhesion protein ApxA of Actinobacillus pleuropneumoniae is required for pathogenesis and is a potential target for vaccine development. Clin Vaccine Immunol 20:287–294
57. Shao M, Wang Y, Wang C, Guo Y, Peng Y, Liu J, Li G, Liu H, Liu S (2010) Evaluation of multicomponent recombinant vaccines against Actinobacillus pleuropneumoniae in mice. Acta Vet Scand 52:52
58. Deslandes V, Denicourt M, Girard C, Harel J, Nash JHE, Jacques M (2010) Transcriptional profiling of Actinobacillus pleuropneumoniae during the acute phase of a natural infection in pigs. BMC Genomics 11:98
59. Stones DH, Krachler AM (2016) Against the tide: the role of bacterial adhesion in host colonization. Biochem Soc Trans 44:1571–1580
60. Roier S, Zingl FG, Cakar F, Durakovic S, Kohl P, Eichmann TO, Klug L, Feldman MF, Schilld S (2016) A novel mechanism for the biogenesis of outer membrane vesicles in Gram-negative bacteria. Nat Commun 7:10515
61. Xie F, Li G, Zhang W, Zhang Y, Zhou L, Liu S, Liu S, Wang C (2016) Outer membrane lipoprotein VacJ is required for the membrane integrity, serum resistance and biofilm formation of Actinobacillus pleuropneumoniae. Vet Microbiol 183:1–8
62. Suzuki T, Murai T, Fukuda I, Tobe T, Yoshikawa M, Sasakawa C (1994) Identification and characterization of a chromosomal virulence gene, vacJ, required for intercellular spreading of Shigella flexneri. Mol Microbiol 11:31–41
63. Shivachandra SB, Kumar A, Yogisharadhya R, Viswas KN (2014) Immunogenicity of highly conserved recombinant vacJ outer membrane lipoprotein of Pasteurella multocida. Vaccine 32:290–296
64. Pors SE, Pedersen U, Skjerning RB, Thøfner ICN, Persson G, Bojesen AM (2016) Outer membrane vesicles of Gallibacterium anatis induce protective immunity in egg-laying hens. Vet Microbiol 195:123–127
65. Negrete-Abaschal G, Garcia RM, Reyes ME, Godinez D, De La Garza M (2000) Membrane vesicles released by Actinobacillus pleuropneumoniae contain proteases and Apx toxins. FEMS Microbiol Lett 191:109–113
66. Van Den Bosch H, Frey J (2003) Interference of outer membrane protein PaA with protective immunity against Actinobacillus pleuropneumoniae infections in vaccinated pigs. Vaccine 21:3601–3607
67. Douidah L, De Zutter L, Baré J, De Vos P, Vandamme P, Vandenberg Q, Van Den Abeele AM, Houf K (2012) Occurrence of putative virulence genes in Arcobacter species isolated from humans and animals. J Clin Microbiol 50:735–741
68. Kavermann H, Bums BP, Angermüller K, Odenbreit S, Fischer W, Melchers K, Haas R (2003) Identification and characterization of Helicobacter pylori genes essential for gastric colonization. J Exp Med J Exp Med 197:813–822
69. Plewa M, Hernalsteens JP, Vandenbussche G, Ruyschaert JM, Cornelis P (2006) The SlyB outer membrane lipoprotein of Burkholderia multivorans contributes to membrane integrity. Res Microbiol 157:582–592
70. Minagawa S, Ogasawara H, Kato A, Yamamoto K, Eguchi Y, Oshima T, Mori H, Ishihama A, Utsumi R (2003) Identification and molecular characterization of the Mg(2+) stimulon of Escherichia coli. J Bacteriol 185:3696–3702